Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.
We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.
GRAIL is headquartered in Sunnyvale, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies.
For more information, please visit grail.com.
Community Guidelines: https://bit.ly/3xigb24
Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives.
Calico’s highly innovative technology labs, its commitment to curiosity-driven discovery science and, with academic and industry partners, its vibrant drug-development pipeline together create an inspiring and exciting place to catalyze and enable medical breakthroughs.
Calico is currently seeking exceptional candidates who share our passion for understanding the science of aging and developing therapeutics to address age-related diseases.
Explore with us! https://www.calicolabs.com/careers
RxSight is a medical device company dedicated to transforming cataract surgery outcomes through the power of adjustability. The company makes the Light Adjustable Lens™ (LAL®), the only FDA-approved intraocular lens (IOL) that can be customized after cataract surgery using ultraviolet (UV) light treatments.
Unlike traditional IOLs—which are fixed at the time of implantation—the LAL allows the treating physician to fine-tune the lens prescription after the eye has fully healed. This means patients receive a vision outcome tailored to their actual, post-surgical visual needs rather than a pre-surgical estimate.
RxSight (Nasdaq: RXST) works with cataract surgeons and ophthalmologists to bring this personalized approach to vision care. For physicians, the LAL platform provides a clinical differentiation that no other premium IOL can match.